RUBIN PAUL D 4

4 · BioAge Labs, Inc. · Filed Mar 3, 2026

AI-generated summary of this filing

Updated Mar 3, 2026

BioAge (BIOA) CMO Paul Rubin Exercises Options and Sells 7,433 Shares

What Happened

Paul D. Rubin, Chief Medical Officer of BioAge Labs (BIOA), exercised a total of 7,433 option-derived shares on 2026-03-02 and immediately sold those shares in the open market.
He exercised 5,433 shares at $4.11 each (cost $22,330) and 2,000 shares at $6.57 each (cost $13,140), for total exercise cost of $35,470. He then sold 7,433 shares at $20.30 each for gross proceeds of $150,890 (approximately $115,420 more than the exercise cost, pre-tax and fees).
This pattern (exercise followed by immediate sale) is effectively a cashless exercise: options were converted to shares and the shares were sold the same day.

Key Details

Transaction date: March 2, 2026 (reported on Form 4 filed March 3, 2026 — timely filing).
Exercise details: 5,433 shares @ $4.11 and 2,000 shares @ $6.57 (acquired); corresponding derivative entries show conversion/disposition at $0.00 (these reflect the option instruments being converted to shares).
Sale: 7,433 shares sold in an open market transaction @ $20.30 for $150,890.
Shares owned after transaction: Not specified in the provided filing excerpt.
Footnotes: Transaction executed under a Rule 10b5-1 trading plan adopted Nov 5, 2024 (F1). One option award was fully vested May 11, 2024 (F2); other option vests monthly as 1/48th of award, starting April 1, 2022 (F3).

Context

For retail investors: exercising and immediately selling option-derived shares is common for liquidity, tax or diversification reasons and does not by itself signal a change in view of the company’s prospects.
This was an officer-level transaction reported under a 10b5-1 plan, which typically specifies pre-set trading parameters.

Form 4

Period: 2026-03-02

Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-03-02$4.11/sh+5,433$22,330→ 5,433 total
Exercise/Conversion
Common Stock
[F1]
2026-03-02$6.57/sh+2,000$13,140→ 7,433 total
Sale
Common Stock
[F1]
2026-03-02$20.30/sh−7,433$150,890→ 0 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F2]
2026-03-02−5,433→ 5,437 total
Exercise: $4.11Exp: 2030-06-30→ Common Stock (5,433 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F3]
2026-03-02−2,000→ 3,383 total
Exercise: $6.57Exp: 2032-05-28→ Common Stock (2,000 underlying)

Footnotes (3)

[F1]The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.
[F2]This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024.
[F3]The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Signature

/s/ Dov A. Goldstein as attorney-in-fact|2026-03-03

1 file